Testosterone: multi-ester blend
Sustanon 250
Sustanon 250 is an oil solution of four testosterone esters; the app lists a half-life of about 15 days, and the UK label gives a peak at 24 to 48 hours and a return to the lower limit of normal in about 21 days.1
Sustanon 250 after one dose: 50% at ~15 days, 25% at 30 days, 12.5% at 45 days.
Drawn from the half-life in the app's model, ~15 days. The model's figures
- Compound
- Sustanon 250
- Symbol
- SUS
- Family
- Testosterone esters
- Parts
- 15
- References
- 19
- Checked
- Last reviewed . Sources are listed below.
Overview
Sustanon 250 is an oil solution of four testosterone esters, with 30 mg propionate, 60 mg phenylpropionate, 60 mg isocaproate and 100 mg decanoate in each 1 mL ampoule, 250 mg of esters in all.1,2 The UK label gives the total amount of testosterone as 176 mg per mL, in refined arachis oil with benzyl alcohol as the other excipient.1 The UK label lists as indications testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests, and supportive therapy for female-to-male transsexuals.1
The blend itself has been given to people in randomized, placebo-controlled studies.3,4 A Milligram search of PubMed on 16 November 2026 for Sustanon[tiab] returned 66 records, 12 of which also matched randomized[tiab], randomised[tiab] or placebo[tiab].
How it works
Sources in this part
The UK label states that Sustanon 250 contains four esters of testosterone with different durations of action, and that the esters are hydrolysed into the natural hormone testosterone as soon as they enter the general circulation.1 It adds that testosterone is metabolised to dihydrotestosterone and estradiol.1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~15 days
- Bioavailability
- 95%
- Typical dose
- 250–500 mg/week
- Route
- IM
- Time to peak
- ~48 h
The figures row is the app's: a half-life of about 15 days (360 hours), a time to peak of about 48 hours, a bioavailability of 95% and a typical dose of 250 to 500 mg per week. Neither the UK label nor the New Zealand data sheet states a half-life or a bioavailability, and the UK label gives a peak at 24 to 48 hours and 1 mL (250 mg of esters) per 3 weeks.1
| Measure | Value | Note |
|---|---|---|
| Half-life | About 15 days (360 hours) | The app's figure; neither label states a half-life. |
| Peak after a single dose | About 70 nmol/l at 24 to 48 hours1,2 | Both labels; the app's time to peak is about 48 hours.2 |
| Return to the lower limit of normal | About 21 days1,2 | Both labels, in males after a single dose.1 |
| Serum testosterone 1 day after 250 mg | 81.4 ± 21.9 nmol/L against 30.0 ± 5.4 nmol/L on placebo3 | Solheim and colleagues, 2020: 8 men on Sustanon 250 and 10 on placebo, values as mean ± SD; the testosterone group started at 19.8 ± 7.6 nmol/L.3 |
| Plasma total testosterone, older men on 250 mg every 2 weeks | 973 ± 54 ng/dL at week 0 and 1149 ± 75 ng/dL after 5 weeks4 | Gharahdaghi and colleagues, 2019: 9 men, 234.9 ± 7 ng/dL at baseline; the text giving these values does not say whether ± is SD or SEM (figure legends use SEM), and the week 0 biopsy was 7 days after an injection.4 |
| Half-life of single esters | Propionate 1 day, phenylpropionate 2.5 days, isocaproate up to 3.1 days; decanoate about 10 days6,5 | Turza and colleagues, 2022 (the three shorter esters, as 'half-life'), and Main and colleagues, 2027 (decanoate, as 'elimination half-life', in its discussion), both citing a 2015 detection study.6,5 |
Gharahdaghi and colleagues write that, "Given the moderately short half-life of T (i.e. 4–5 days)", the testosterone was administered every two weeks, where T is the paper's abbreviation for testosterone, so the 4 to 5 days is a figure for testosterone and is placed here beside the app's 15 days for the blend.4
Detection windows in blood
Forsdahl and colleagues, of a doping control laboratory in Austria and the Center for Preventive Doping Research at the German Sport University, in Drug Testing and Analysis in 2015, gave six participants a single intramuscular injection of either 1000 mg testosterone undecanoate or the four-ester mixture, and collected blood over 60 days; the PubMed record does not say how many received Sustanon.7 All investigated esters could be detected and the detection time depended on the type of ester; measured concentrations of especially short-chained esters were influenced by the type of blood collection device, while the detection window was comparable.7 Solheim and colleagues, including Anti-Doping Denmark staff, in the same journal in 2022, took dried blood spots from 9 men given two intramuscular injections of Sustanon 250 and 10 given placebo; with a research nanoLC-HRMS/MS method, Sustanon was detected in all subjects for at least 5 days, with a detection window up to 14 days for three of the four esters and none stated for the fourth.8
The four esters apart
Turza and colleagues, in Materials in 2022, state that half-lives are around 1 day for propionate, 2.5 days for phenylpropionate and up to 3.1 days for isocaproate, and that the longer the ester, the longer the half-life.6 Main and colleagues, in Andrology in 2027, state in their discussion, citing Forsdahl and colleagues, that testosterone decanoate has a tendency to accumulate within adipose tissue, resulting in an extended elimination half-life of approximately 10 days.5 Testosterone decanoate as the only ester was given in one trial among the sources cited, by Anderson and colleagues in Contraception in 2002, in which 20 healthy Chinese men had 400 mg intramuscularly every 4 weeks with two etonogestrel implants and peak concentrations 1 week after the fourth injection were 31 ± 2 nmol/liter, with ± not defined in the record.9 That study ended after 12 to 18 weeks because some men had elevated liver enzyme tests, and it is a result for decanoate with implants, not for the four-ester blend.9
The curve below plots a one-compartment model with the app's half-life of 360 hours and time to peak of 48 hours, at the intervals in the UK label and the trials cited.1
What a Sustanon 250 ampoule contains per mL
Sources in this part
The UK product is Sustanon 250, 250mg/ml solution for injection, supplied as 1 ml colourless glass ampoules with one ampoule in a box.1 The converter below multiplies a volume in mL by the label strength of 250 mg of esters per mL.1
Strength converter
UK label strength (esters): 250 mg per mL1
Arithmetic only: the amount is the volume times the strength. The vial's own label states its strength.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Reid and colleagues, 199610 | Randomized crossover against control periods, University of Auckland10 | 15 asthmatic men on long-term glucocorticoid treatment10 | 250 mg a month by intramuscular depot injection for 12 months, then crossover for 12 months10 | Lumbar spine bone density rose 5.0% ± 1.4% (mean ± SEM; P = .005) on testosterone and did not change in the control period (between-groups difference, P = .05).10 |
| Anderson and colleagues, 199611 | Open prospective trial, Freeman Hospital, Newcastle11 | 23 men aged 34 to 73 with vertebral crush fractures; 21 completed11 | 250 mg intramuscularly every 2 weeks for 6 months11 | Lumbar spine bone density rose from 0.799 to 0.839 g/cm2 (p < 0.001) and hip density did not change; HDL cholesterol fell by 0.087 mmol/L (p < 0.05).11 |
| Gharahdaghi and colleagues, 20194 | Randomized, double-blind, placebo-controlled, with resistance training4 | 18 healthy non-hypogonadal men aged 65 to 754 | Sustanon 250 mg (9 men) or saline (9 men) every 2 weeks for 6 weeks of whole-body resistance training4 | Total fat-free mass rose with testosterone (P = 0.007) and total fat mass fell (P = 0.02); no adverse events were noted.4 |
| Solheim and colleagues, 2020 (Frontiers in Physiology)3 | Randomized, double-blind, placebo-controlled3 | 19 eugonadal men aged 20 to 30: 9 given Sustanon 250 and 10 placebo3 | A single 250 mg injection, with tests 24 hours later3 | No enhancement of jump height, sprint power or isometric elbow flexion 24 hours after injection; 7 of 8 in the testosterone group reported injection site discomfort against 1 of 10 on placebo.3 |
| Same trial: Solheim and colleagues, 2020 (Drug Testing and Analysis), and Main and colleagues, 202713,5 | Randomized, placebo-controlled; athlete biological passport markers, then small noncoding RNA sequencing13,5 | 19 eugonadal men aged 20 to 3013,5 | 250 mg on days 0 and 21, with samples to day 14 after injection and serum on days 0, 1 and 4213,5 | The steroidal profile was flagged suspicious in all Sustanon-treated subjects and the haematological profile in six of nine; 19 Sustanon-responsive small noncoding RNAs were identified 24 hours after injection and 160 remained altered on day 42 with testosterone back at baseline; the day 42 comparison used 4 Sustanon-arm men, and the authors write that results need cautious interpretation.13,5 |
Results were mixed or null as well as positive: Solheim and colleagues found no acute performance effect, Anderson and colleagues reported a fall in HDL cholesterol alongside the bone density rise, and Bunck and colleagues, in 30 ovariectomized female-to-male transsexuals who all received Sustanon 250 every 2 weeks, found no significant changes in bone metabolism or vascular parameters from adding anastrozole against placebo, although individual estradiol correlated with several vascular parameters in the anastrozole group.3,14,11
Deeper analysis: the randomized trial in 19 young men
Solheim and colleagues, of the University of Copenhagen and Anti Doping Denmark among others, published the trial in Frontiers in Physiology in 2020.3 Twenty-four men volunteered, four were excluded after medical examination, one dropped out and 19 completed, and one of those could not complete the post-injection performance tests because of illness, which left 18 in that analysis.3 The authors conclude that the injection did not enhance performance acutely and state that potential delayed effects were not evaluated.3 On dose, they write that "It may be questioned whether the applied dose is of high relevance as athletes' steroid regimens are found to range from 250 to more than 2,500 mg/week".3 The study was funded by the Partnership for Clean Competition, the Innovation Fund Denmark's Industrial PhD program and Anti Doping Denmark, two authors were employed by Anti Doping Denmark during the intervention and manuscript preparation, and the remaining authors declare no commercial or financial relationships.3 The 2020 and 2022 Drug Testing and Analysis papers from the same group list Anti Doping Denmark among their author affiliations.13,8 Main and colleagues, analysing stored serum from the same trial, list a rather small sample size (n = 19) and a drop to n = 12 on day 42 after sample exclusion as limitations, say this may partly explain the gap between 19 sncRNAs on day 1 and 160 on day 42, and write that the results need cautious interpretation; they were funded by, among others, the Novo Nordisk Foundation.5 On day 42 the Sustanon arm had 4 men and the placebo arm 8, a greater number of sncRNAs were altered in the placebo arm than in the Sustanon arm, and 68% of the upregulated and 54% of the downregulated Sustanon-arm sncRNAs overlapped with the placebo group.5
Deeper analysis: Gharahdaghi and colleagues, 2019
Gharahdaghi and colleagues, of the University of Nottingham, published in the Journal of Cachexia, Sarcopenia and Muscle in 2019 a randomized, double-blinded trial in 18 non-hypogonadal older men aged 65 to 75, registered at ClinicalTrials.gov as NCT02152839.4 Sum strength (P = 0.0009) and maximal voluntary contraction (P = 0.002) increased more in the testosterone group, and muscle protein synthesis and breakdown rates were both higher with testosterone, which the authors say led to higher net turnover and protein accretion.4 The authors state that no adverse events were noted and add that randomized controlled trials have been insufficiently powered to detect differences in the rates of adverse events, that testosterone therapy has been associated with (non-significant) increases in cardiovascular risk and prostate hypertrophy, that some trials report more stroke or myocardial infarction while others are uncertain, and that older men receiving it need careful monitoring because of its potential risks.4 The work was supported by the Medical Research Council and the National Institute for Health Research Nottingham Biomedical Research Centre, and the authors declare no conflict of interest.4
Deeper analysis: Reid and colleagues, 1996
Reid and colleagues, of the Department of Medicine at the University of Auckland, published the trial in the Archives of Internal Medicine in 1996.10 Lumbar spine bone density rose 5.0% ± 1.4% on testosterone with no change in the control period, and in the control period body fat mass rose by 2.1 ± 0.06 kg (P = .01) and lean body mass fell by 1.4 ± 0.5 kg (P = .02), both changes reversed by testosterone treatment (P < .03).10 The PubMed record gives no funding statement, no author disclosures and no stated limitations.10
Deeper analysis: Anderson and colleagues, 1996 and 1997
Anderson, Francis and colleagues, of the Musculoskeletal Unit at the Freeman Hospital in Newcastle upon Tyne, published two papers on men treated with Sustanon 250 every 2 weeks for 6 months, in Bone in 1996 and in the Journal of Bone and Mineral Research in 1997.11,15 The 1997 paper reports that serum testosterone rose by 55%, sex hormone binding globulin fell by 20%, free androgen rose by 90% and serum estradiol rose by 45%, with treatment well tolerated and side effects uncommon.15 The authors of the 1996 paper conclude that the treatment "warrants further evaluation in a randomized, controlled trial", and the PubMed records give no funding statement.11,15
Doses reported in studies and on labels
| Source | Dose | Frequency | Length |
|---|---|---|---|
| UK label, adults1 | 1 mL (250 mg of esters)1 | One injection per 3 weeks, by deep intramuscular injection1 | Not stated |
| UK label, female-to-male transsexuals1 | 1 mL1 | Every 2 weeks to every 4 weeks across specialist centres1 | Not stated |
| New Zealand data sheet, adults2 | 1 mL2 | One injection per three weeks2 | Not stated |
| Solheim and colleagues, 202013 | 250 mg13 | Days 0 and 21 (single injection in the Frontiers in Physiology analysis)13,3 | Samples to day 14 after injection13 |
| Gharahdaghi and colleagues, 20194 | 250 mg4 | Every 2 weeks4 | 6 weeks4 |
| Anderson and colleagues, 1996 and 199711 | 250 mg11 | Every 2 weeks15 | 6 months15 |
| Reid and colleagues, 199610 | 250 mg10 | Monthly10 | 12 months, then crossover for 12 months10 |
The app's typical dose is 250 to 500 mg per week, and the UK label and the New Zealand data sheet instead give 1 mL, which is 250 mg of esters, per 3 weeks for adults, about 83 mg per week.1,2 The trials cited used 250 mg every 2 weeks, monthly or once or twice, and the weekly schedule appears in a case report.4,10,13,16
Side effects reported
Label statements
The UK label states that, due to the nature of Sustanon 250, side effects cannot be quickly reversed by discontinuing medication, and that injectables in general may cause a local reaction at the injection site.1 Its table of adverse reactions associated with androgen therapy in general lists weight increased as common, pulmonary oil microembolism as rare, and polycythaemia, fluid retention, hypertension, gynaecomastia, oligospermia and hepatic function abnormal, among others, with frequency not known.1 Its investigations rows (lipids abnormal, PSA increased, haematocrit increased, red blood cell count increased and haemoglobin increased) show the frequencies not known and common.1 The precautions also name thrombotic events in patients with thrombophilia or risk factors for venous thromboembolism, a possible rise in blood pressure, reports that testosterone can cause or exacerbate sleep apnoea, and signs of virilisation, including voice deepening that may be irreversible.1 Its contraindications are pregnancy, known or suspected carcinoma of the prostate or breast, breast-feeding, and hypersensitivity including to arachis oil.1 On abuse, the UK label states that testosterone abuse can lead to serious adverse reactions including cardiovascular events with fatal outcomes in some cases, hepatic and psychiatric events, and may result in dependence and withdrawal symptoms, and the New Zealand data sheet lists myocardial infarction, secondary hypogonadism and peliosis hepatis among those reported in that context.1,2 The UK label also states that in men, treatment with androgens can lead to fertility disorders by repressing sperm-formation.1
Reported in studies
In the Solheim randomized trial, 7 of 8 men given Sustanon 250 reported discomfort at the site of injection, against 1 of 10 on placebo.3 Gharahdaghi and colleagues state that no adverse events were noted, Richardson and colleagues report no adverse events from either medication in 13 men, and Anderson and colleagues report that treatment was well tolerated and side effects were uncommon, alongside a fall in HDL cholesterol and a hematocrit rise from 0.434 to 0.456.4,12,15,11 The 1996 Anderson paper also reports a rise in plasma viscosity that was significant at 3 months but not at 6 months and a rise in the free androgen index from 0.504 to 0.887, and in the decanoate trial with implants haemoglobin rose 9%, haematocrit 15% and 16 of 20 men were azoospermic at 12 weeks.11,9
A case report and an animal study
Alrabadi and colleagues, in Biomedical Reports in 2020, describe a 26-year-old physically active physician without classical coronary risk factors who presented with a massive acute myocardial infarction with cardiogenic shock, and the report states that the patient admitted that he was a chronic user of the anabolic steroid sustanon (250 mg, once/week for 6 months) and amino acid supplements.16 It is a report of one patient.16 In rats, Kamali Hosseinzadeh and colleagues gave adult males 10, 20 or 30 mg/kg body weight of Sustanon for 8 weeks and report significant reductions in testicular length, diameter, weight, sperm count, luteinizing hormone and follicle-stimulating hormone concentrations in the treated groups, which is an animal result.17
Bloodwork and markers
Sources in this part
The UK label lists monitoring of testosterone level at baseline and at regular intervals and, for physicians to consider, digital rectal examination of the prostate and PSA, and haematocrit and haemoglobin, before treatment, at quarterly intervals for the first 12 months and yearly thereafter.1 For long-term androgen therapy it adds haemoglobin, haematocrit, liver function tests and lipid profile.1 In the anti-doping trial of Solheim and colleagues, reticulocyte percentage appeared as the best marker of the haematological module for implying testosterone ester misuse, and the authors write that unexpected fluctuations in it can indicate testosterone doping if samples are collected 3-10 days after injection.13
Regulatory and anti-doping status
Testosterone is named in section S1.1 of the World Anti-Doping Agency's 2026 Prohibited List, anabolic agents prohibited at all times, in and out of competition, when administered exogenously, and the section covers other substances with a similar structure or effect including their esters.18 The UK label states that Sustanon 250 can interfere with anti-doping testing, in a passage addressed to patients who take part in competitions governed by WADA.1 In the United States, 21 CFR 1308.13 places anabolic steroids in Schedule III unless specifically excepted or listed in another schedule, including testosterone and its salts, esters and ethers.19
Storage and handling
Sources in this part
The UK label gives storage below 30°C, no refrigeration or freezing, and storage in the original package to protect from light, with a shelf life of 5 years.1
What is not known
Sources in this part
A Milligram search of PubMed on 16 November 2026 for Sustanon[tiab] together with pharmacokinetic*[tiab], half-life[tiab] or half life[tiab] returned 2 records, a 2003 paper on delivery of testosterone replacement therapy and a 1992 method for measuring anabolic steroids in urine, and neither summary reports a half-life of the blend. Neither the UK label nor the New Zealand data sheet states a half-life or a bioavailability, so the app's 15 days and 95% have no figure from those documents beside them. The half-lives of the single esters come from statements in two papers that cite a detection study, and the one decanoate trial in the sources cited used a different preparation with implants.6,9
Frequently asked questions
What is the half-life of Sustanon 250?
The app lists a half-life of about 15 days (360 hours) for Sustanon 250, and neither the UK label nor the New Zealand data sheet states a half-life. The UK label states a peak at approximately 24 to 48 hours and a return to the lower limit of the normal range in approximately 21 days after a single dose, and Main and colleagues state an elimination half-life of approximately 10 days for the decanoate ester.1,5
What is in Sustanon 250?
Each 1 mL ampoule contains 30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate in refined arachis oil.1
When does Sustanon 250 peak?
The UK label states that peak total plasma testosterone of approximately 70 nmol/l is reached approximately 24 to 48 hours after a single dose, against the app's time to peak of about 48 hours.1
How long is Sustanon 250 detectable?
In a research dried blood spot method (nanoLC-HRMS/MS) tested in 9 men given two injections, Sustanon was detected in all subjects for at least 5 days, with a detection window up to 14 days for three of the four esters and none stated for the fourth.8 The UK label's 21 days is a different quantity, the time for plasma testosterone to return to the lower limit of the normal range in males after a single dose, and not a detection time for an ester.1
Is Sustanon 250 banned by WADA?
Sustanon 250 falls under the esters clause of section S1.1 of the WADA 2026 Prohibited List, which prohibits testosterone and other substances with a similar chemical structure or similar biological effect(s) including their esters, at all times, in and out of competition, when administered exogenously.1,18 The list text names testosterone but does not name Sustanon or any of its four esters individually.18
What are the side effects of Sustanon 250?
The UK label lists, among adverse reactions associated with androgen therapy in general, weight increased as common, pulmonary oil microembolism as rare, and polycythaemia and fluid retention, among others, as frequency not known, and states that side effects cannot be quickly reversed by discontinuing medication.1 In the randomized trial of Solheim and colleagues, 7 of 8 men given Sustanon 250 reported discomfort at the site of injection, against 1 of 10 on placebo.3
Does Sustanon 250 contain peanut oil?
Yes, the UK label states that Sustanon 250 contains refined arachis oil, which is peanut oil, and that it is contraindicated in patients allergic to peanuts or soya.1
Has Sustanon 250 been studied in people?
Yes, including randomized, placebo-controlled trials.3,4 A Milligram search of PubMed on 16 November 2026 for Sustanon[tiab] returned 66 records, 12 of which also matched randomized[tiab], randomised[tiab] or placebo[tiab]. The trials cited here enrolled 6 to 30 people, such as 18 older men on 250 mg every 2 weeks for 6 weeks and 15 men on glucocorticoids on 250 mg a month for 12 months.4,10,7,14
Guides, tools and comparisons
- Sustanon injection dosageA guide that answers a question on this compound.
- Calculator for Sustanon 250A calculator set up for this compound.
- Sustanon 250 vs testosterone cypionateA side-by-side with another compound.
- Previous in Testosterone esters: Testosterone Undecanoate (Oral)The compound before this one in the class.
- Next in Testosterone esters: Testosterone CypionateThe compound after this one in the class.
References
- Aspen Pharma Trading Limited. Sustanon 250, 250mg/ml solution for injection. Summary of Product Characteristics, electronic Medicines Compendium (UK), text revised December 2025. emc SmPC
- Pharmacy Retailing (NZ) Ltd. Sustanon 250 (250 mg testosterone esters solution for injection), New Zealand data sheet. Medsafe, revised 14 January 2026. Medsafe data sheet
- Solheim SA, et al. An intramuscular injection of mixed testosterone esters does not acutely enhance strength and power in recreationally active young men. Front Physiol 2020. PMC7538707
- Gharahdaghi N, et al. Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men. J Cachexia Sarcopenia Muscle 2019. PMC6903447
- Main AM, et al. Temporal effects of exogenous testosterone on the circulating small noncoding RNA landscape in a placebo-controlled human study. Andrology 2027. PMC13748923
- Turza A, et al. Structural aspects and intermolecular energy for some short testosterone esters. Materials (Basel) 2022. PMC9611952
- Forsdahl G, et al. Detection of testosterone esters in blood. Drug Test Anal 2015. PMID 26695486
- Solheim SA, et al. Stability and detectability of testosterone esters in dried blood spots after intramuscular injections. Drug Test Anal 2022. PMID 33733610
- Anderson RA, et al. Investigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implants. Contraception 2002. PMID 12443967
- Reid IR, et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996. PMID 8639011
- Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis: effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone 1996. PMID 8833211
- Richardson D, et al. Letrozole versus testosterone: a single-center pilot study of HIV-infected men who have sex with men on HAART with hypoactive sexual desire disorder and raised estradiol levels. J Sex Med 2007. PMID 17367446
- Solheim SA, et al. Changes in blood parameters after intramuscular testosterone ester injections - Implications for anti-doping. Drug Test Anal 2020. PMID 32307878
- Bunck MC, et al. The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals. Eur J Endocrinol 2006. PMID 16556720
- Anderson FH, et al. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res 1997. PMID 9076591
- Alrabadi N, et al. Acute myocardial infarction with cardiogenic shock in a young physically active physician concurrently using the anabolic steroid sustanon: a case report. Biomed Rep 2020. PMID 32765853
- Kamali Hosseinzadeh F, et al. Sustanon suppresses spermatogenesis and increases cell death. Transl Androl Urol 2024. PMID 39816223
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA 2026 list
- 21 CFR 1308.13 Schedule III. Electronic Code of Federal Regulations, current text. eCFR 1308.13